Real-world experience with cefepime/zidebactam under compassionate use
Introduction: Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options. Methods: We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes. Results: Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation. Conclusions: In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.
Authors
- Surabhi Madan
- Vijil Rahulan (ORCID: https://orcid.org/0000-0002-8441-9874)
- Sowmya Sridharan (ORCID: https://orcid.org/0000-0002-8097-3261)
- Anjely Pulparampil Sebastian (ORCID: https://orcid.org/0000-0002-8022-1086)
- Siddhant Shetty
- William R. Miller (ORCID: https://orcid.org/0000-0002-1518-2973)
- Kedar Toraskar (ORCID: https://orcid.org/0000-0001-6227-9199)
- Vishnu Rao Polati (ORCID: https://orcid.org/0000-0002-8853-3308)
- Manish Soneja (ORCID: https://orcid.org/0000-0002-8619-7929)
- Sandeep Kumar Mitra
- Praveen Kumar Tirlangi
- Harshith B. Kadnur (ORCID: https://orcid.org/0000-0003-0617-1241)
- Timothy William (ORCID: https://orcid.org/0000-0002-2195-6736)
- Honey Satish Savla
- Radhika Sarda (ORCID: https://orcid.org/0000-0003-4760-797X)
- Balaji Veeraraghavan (ORCID: https://orcid.org/0000-0002-8662-4257)
- Vidya Krishna (ORCID: https://orcid.org/0000-0002-0203-3952)
- Abi Manesh S (ORCID: https://orcid.org/0000-0001-9970-9674)
- Suneetha Narreddy (ORCID: https://orcid.org/0000-0003-4237-1814)
- Monalisa Sahu (ORCID: https://orcid.org/0000-0002-5546-4641)
- David van Duin (ORCID: https://orcid.org/0000-0003-4784-3227)
- Nitin Ranjan Gupta (ORCID: https://orcid.org/0000-0002-9687-2836)
- Erlinda Rose Ulloa (ORCID: https://orcid.org/0000-0002-0330-278X)
- Umang Agrawal (ORCID: https://orcid.org/0000-0002-2105-3932)
- Harshad S Limaye
- Ayesha Sunavala (ORCID: https://orcid.org/0000-0003-3912-7642)
- Thomas P. Lodise (ORCID: https://orcid.org/0000-0002-4730-0655)
- Elisabeth E. Adderson (ORCID: https://orcid.org/0000-0001-9691-7814)
- Tanu Singhal (ORCID: https://orcid.org/0000-0003-4127-1977)
- Samuel L Aitken (ORCID: https://orcid.org/0000-0002-8659-4238)
- Dilip Kumar Dubey (ORCID: https://orcid.org/0009-0002-0790-4611)
- Vikas Deswal (ORCID: https://orcid.org/0000-0002-5758-2262)
- Subramanian Swaminathan
- Nitin Bansal
- Pooja H Shah
- Raman Gaikwad
- Shalmali B Inamdar
- Irfana Mohammed
- Ashwini R Tayade
- Pratik Y Patil
- Rajeev Soman
- Abdul Ghafur
- Rasika Sirsat
- Vasant Nagvekar
- Neha Gupta
- Andrew Shorr
- Ankit Mittal
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2026-11-17
- DOI
- https://doi.org/10.17615/9bwt-te51
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Purdue University
- California Institute of Technology
- Gun och Bertil Stohnes Stiftelse
- Wellcome Trust
- Ögonfonden
- Stiftelsen Tornspiran
- Ohio Soybean Council
- Heritage Medical Research Institute
- National Energy Research Scientific Computing Center
- University of Leeds
- Indian Council of Medical Research
- Deutsche Forschungsgemeinschaft
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- China Scholarship Council
- Norges Forskningsråd
- Suzhou Municipal Science and Technology Bureau
- Gansu University of Chinese Medicine
- Narodowa Agencja Wymiany Akademickiej
- Agencia Nacional de Investigación y Desarrollo
- Ministero dell'Università e della Ricerca
- National Institutes of Health
- Office of Science
- Engineering and Physical Sciences Research Council
- Basic Research Program of Jiangsu Province
- Sanming Project of Medicine in Shenzhen
- National Key Research and Development Program of China
- Institute for Materials Research, Tohoku University
- National Heart, Lung, and Blood Institute
- National Institute of General Medical Sciences
- National Institute of Allergy and Infectious Diseases
- Office of Advanced Cyberinfrastructure
- Division of Chemical, Bioengineering, Environmental, and Transport Systems
- Basic Energy Sciences
- Fondo Nacional de Desarrollo Científico y Tecnológico
- H2020 European Research Council